Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Myeloid-derived suppressor cells as therapeutic target in hematological malignancies.
De Veirman K, Van Valckenborgh E, Lahmar Q, Geeraerts X, De Bruyne E, Menu E, Van Riet I, Vanderkerken K, Van Ginderachter JA. De Veirman K, et al. Among authors: geeraerts x. Front Oncol. 2014 Dec 8;4:349. doi: 10.3389/fonc.2014.00349. eCollection 2014. Front Oncol. 2014. PMID: 25538893 Free PMC article. Review.
Beyond the M-CSF receptor - novel therapeutic targets in tumor-associated macrophages.
Bonelli S, Geeraerts X, Bolli E, Keirsse J, Kiss M, Pombo Antunes AR, Van Damme H, De Vlaminck K, Movahedi K, Laoui D, Raes G, Van Ginderachter JA. Bonelli S, et al. Among authors: geeraerts x. FEBS J. 2018 Feb;285(4):777-787. doi: 10.1111/febs.14202. Epub 2017 Sep 6. FEBS J. 2018. PMID: 28834216 Free article. Review.
The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity.
Laoui D, Keirsse J, Morias Y, Van Overmeire E, Geeraerts X, Elkrim Y, Kiss M, Bolli E, Lahmar Q, Sichien D, Serneels J, Scott CL, Boon L, De Baetselier P, Mazzone M, Guilliams M, Van Ginderachter JA. Laoui D, et al. Among authors: geeraerts x. Nat Commun. 2016 Dec 23;7:13720. doi: 10.1038/ncomms13720. Nat Commun. 2016. PMID: 28008905 Free PMC article.
The role of hepatic macrophages in liver metastasis.
Keirsse J, Van Damme H, Geeraerts X, Beschin A, Raes G, Van Ginderachter JA. Keirsse J, et al. Among authors: geeraerts x. Cell Immunol. 2018 Aug;330:202-215. doi: 10.1016/j.cellimm.2018.03.010. Epub 2018 Apr 6. Cell Immunol. 2018. PMID: 29661474 Review.
Single-domain antibody fusion proteins can target and shuttle functional proteins into macrophage mannose receptor expressing macrophages.
De Vlaeminck Y, Lecocq Q, Giron P, Heirman C, Geeraerts X, Bolli E, Movahedi K, Massa S, Schoonooghe S, Thielemans K, Goyvaerts C, Van Ginderachter JA, Breckpot K. De Vlaeminck Y, et al. Among authors: geeraerts x. J Control Release. 2019 Apr 10;299:107-120. doi: 10.1016/j.jconrel.2019.02.023. Epub 2019 Feb 21. J Control Release. 2019. PMID: 30797866
Macrophages are metabolically heterogeneous within the tumor microenvironment.
Geeraerts X, Fernández-Garcia J, Hartmann FJ, de Goede KE, Martens L, Elkrim Y, Debraekeleer A, Stijlemans B, Vandekeere A, Rinaldi G, De Rycke R, Planque M, Broekaert D, Meinster E, Clappaert E, Bardet P, Murgaski A, Gysemans C, Nana FA, Saeys Y, Bendall SC, Laoui D, Van den Bossche J, Fendt SM, Van Ginderachter JA. Geeraerts X, et al. Cell Rep. 2021 Dec 28;37(13):110171. doi: 10.1016/j.celrep.2021.110171. Cell Rep. 2021. PMID: 34965415 Free article.
Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma.
Duerinck J, Lescrauwaet L, Dirven I, Del'haye J, Stevens L, Geeraerts X, Vaeyens F, Geens W, Brock S, Vanbinst AM, Everaert H, Caljon B, Bruneau M, Lebrun L, Salmon I, Kockx M, Tuyaerts S, Neyns B. Duerinck J, et al. Among authors: geeraerts x. Neuro Oncol. 2024 Dec 5;26(12):2208-2221. doi: 10.1093/neuonc/noae177. Neuro Oncol. 2024. PMID: 39406392 Clinical Trial.
A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors.
Vounckx M, Tijtgat J, Stevens L, Dirven I, Ilsen B, Vandenbroucke F, Raeymaeckers S, Vekens K, Forsyth R, Geeraerts X, Van Riet I, Schwarze JK, Tuyaerts S, Decoster L, De Ridder M, Dufait I, Neyns B. Vounckx M, et al. Among authors: geeraerts x. Cancer Immunol Immunother. 2024 Jul 2;73(9):167. doi: 10.1007/s00262-024-03751-0. Cancer Immunol Immunother. 2024. PMID: 38954010 Free PMC article. Clinical Trial.
Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma.
Tijtgat J, Geeraerts X, Boisson A, Stevens L, Vounckx M, Dirven I, Schwarze JK, Raeymaeckers S, Forsyth R, Van Riet I, Tuyaerts S, Willard-Gallo K, Neyns B. Tijtgat J, et al. Among authors: geeraerts x. J Immunother Cancer. 2024 Jan 11;12(1):e008148. doi: 10.1136/jitc-2023-008148. J Immunother Cancer. 2024. PMID: 38212127 Free PMC article.
11 results